Soligenix Yönetim

Yönetim kriter kontrolleri 3/4

Soligenix CEO'su Christopher Schaber, Aug2006 tarihinde atandı, in görev süresi 18.25 yıldır. in toplam yıllık tazminatı $ 700.49K olup, şirket hissesi ve opsiyonları dahil olmak üzere 74.2% maaş ve 25.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler $ 1.25K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.4 yıl ve 15.4 yıldır.

Anahtar bilgiler

Christopher Schaber

İcra Kurulu Başkanı

US$700.5k

Toplam tazminat

CEO maaş yüzdesi	74.2%
CEO görev süresi	18.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	10.4yrs
Yönetim Kurulu ortalama görev süresi	15.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Christopher Schaber'un ücretlendirmesi Soligenix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

Tazminat ve Piyasa: Christopher 'nin toplam tazminatı ($USD 700.49K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 356.31K ).

Tazminat ve Kazançlar: Christopher 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Christopher Schaber (58 yo)

18.3yrs

Görev süresi

US$700,485

Tazminat

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.3k
Jonathan Guarino	Senior VP	5.2yrs	US$354.69k	0.0018% $ 152.0
Oreola Donini	Senior VP & Chief Scientific Officer	9.9yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.8yrs	US$249.94k	0.0014% $ 112.1

10.4yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 0A6I 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.3k
Jerome Zeldis	Independent Director	13.4yrs	US$72.50k	0.0038% $ 318.1
Gregory Lapointe	Independent Director	15.7yrs	US$77.50k	0.0012% $ 103.0
Robert Rubin	Independent Director	15.1yrs	US$80.00k	0.00076% $ 63.1
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	Veri yok	Veri yok
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	Veri yok	Veri yok
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	Veri yok	Veri yok
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	Veri yok	Veri yok

15.4yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0A6I 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15.4 yıldır).

Soligenix Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023)

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023)

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022)

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Insufficient new directors

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022)

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022)

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Insufficient new directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş